# AbVitro

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abvitro

- Industry: Biotechnology
- Headquarters: Boston, US
- Total disclosed funding: $7.4M
- Latest round: Series A (Jun 2, 2013)
- Investors on record: 1

## About

Founded in 2010 and based in Massachusetts, US, AbVitro, Inc. develops an antibody discovery platform for the treatment of autoimmune diseases and cancer. AbVitro’s technology allows for the identification of fully human, natively paired T-cell receptors (TCRs) and chimeric antigen receptor (CAR) T-binders directly from cancer patients. In June 2013, AbVitro, Inc. raised USD 1.873 million in Series A financing from Santé Ventures, and in 2016, the company was acquired by Juno Therapeutics for USD 135 million in cash and stock.

## Funding rounds

- Series A, Jun 2, 2013, $1.9M — Sante Ventures
- Series A, Feb 9, 2012, $5.5M — Sante Ventures

## Investors

- Sante Ventures (https://capitalatlas.ai/funds/sante-ventures) — Series A